Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_22
Snippet: The focus of David's lecture then switched to HBV. David commented that two nucleotide analogues, used widely for HBV therapy, came from Tony Hol y -adefovir and tenofovir. Initially, lamivudine was approved for HBV therapy but viral resistance became a major problem, about two-thirds of the patients having resistant virus after four years of treatment. With adefovir, the resistance was much less, at about 30% after five years but a better treatm.....
Document: The focus of David's lecture then switched to HBV. David commented that two nucleotide analogues, used widely for HBV therapy, came from Tony Hol y -adefovir and tenofovir. Initially, lamivudine was approved for HBV therapy but viral resistance became a major problem, about two-thirds of the patients having resistant virus after four years of treatment. With adefovir, the resistance was much less, at about 30% after five years but a better treatment was needed. With entecavir and tenofovir, the resistance levels remain very low, just a handful of patients having resistant virus. Recently, tenofovir alafenamide (a new prodrug) has been approved -the efficacy is comparable to that with tenofovir but the safety profile is significantly improved.
Search related documents:
Co phrase search for related documents- HBV therapy and major problem: 1
- HBV therapy and new prodrug: 1
- HBV therapy and new prodrug alafenamide: 1
- HBV therapy and new prodrug alafenamide tenofovir: 1
- HBV therapy and nucleotide analogue: 1
- low remain and major problem: 1
- low remain and resistance level: 1
- major problem and resistance level: 1
- major problem and resistant virus: 1
- nucleotide analogue and resistant virus: 1
Co phrase search for related documents, hyperlinks ordered by date